References
Key articles
Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.Full text Abstract
National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. Jun 2021 [internet publication].Full text
Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.Full text Abstract
Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75. Abstract
Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-26. Abstract
Kuck KH, Brugada J, Furnkranz A, et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45.Full text Abstract
Luik A, Radzewtiz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF Study. Circulation. 2015 Oct 6;132(14):1311-9.Full text Abstract
Reference articles
1. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology/American Heart Association Joint Committee on clinical practice guidelines. Circulation. 2024 Jan 2;149(1):e1-156.Full text Abstract
2. Hindricks G, Potpara T, Dagres N, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J. 2021 Feb 1;42(5):373-498.Full text Abstract
3. Lévy S, Steinbeck G, Santini L, et al. Management of atrial fibrillation: two decades of progress - a scientific statement from the European Cardiac Arrhythmia Society. J Interv Card Electrophysiol. 2022 Oct;65(1):287-326. Abstract
4. Marini C, De Santis F, Sacco S, et al. Contribution of atrial fibrillation to incidence and outcome of ischemic stroke: results from a population-based study. Stroke. 2005 Jun;36(6):1115-9.Full text Abstract
5. Paciaroni M, Agnelli G, Caso V, et al. Atrial fibrillation in patients with first-ever stroke: frequency, antithrombotic treatment before the event and effect on clinical outcome. J Thromb Haemost. 2005 Jun;3(6):1218-23.Full text Abstract
6. Kornej J, Börschel CS, Benjamin EJ, et al. Epidemiology of atrial fibrillation in the 21st century: novel methods and new insights. Circ Res. 2020 Jun 19;127(1):4-20.Full text Abstract
7. Elliott AD, Middeldorp ME, Van Gelder IC, et al. Epidemiology and modifiable risk factors for atrial fibrillation. Nat Rev Cardiol. 2023 Jun;20(6):404-17. Abstract
8. Ohlrogge AH, Brederecke J, Schnabel RB. Global burden of atrial fibrillation and flutter by national income: results from the global burden of disease 2019 database. J Am Heart Assoc. 2023 Sep 5;12(17):e030438.Full text Abstract
9. Lippi G, Sanchis-Gomar F, Cervellin G. Global epidemiology of atrial fibrillation: an increasing epidemic and public health challenge. Int J Stroke. 2021 Feb;16(2):217-21. Abstract
10. Kannel WB, Wolf PA, Benjamin EJ, et al. Prevalence, incidence, prognosis, and predisposing conditions for atrial fibrillation: population-based estimates. Am J Cardiol. 1998 Oct 16;82(8A):2N-9N. Abstract
11. Heeringa J, van der Kuip DA, Hofman A, et al. Prevalence, incidence and lifetime risk of atrial fibrillation: the Rotterdam study. Eur Heart J. 2006 Apr;27(8):949-53.Full text Abstract
12. Lloyd-Jones DM, Wang TJ, Leip EP, et al. Lifetime risk for the development of atrial fibrillation: the Framingham Heart Study. Circulation. 2004 Aug 31;110(9):1042-6.Full text Abstract
13. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995 Mar 13;155(5):469-73. Abstract
14. Hobbs FD, Fitzmaurice DA, Jowett S, et al. A randomised controlled trial and cost-effectiveness study of systematic screening (targeted and total population screening) versus routine practice for the detection of atrial fibrillation in people aged 65 and over: the SAFE study. Health Technol Assess. 2005 Oct;9(40):iii-iv;ix-x;1-74. Abstract
15. Stewart S, Hart CL, Hole DJ, et al. Population prevalence, incidence, and predictors of atrial fibrillation in the Renfrew/Paisley study. Heart. 2001 Nov;86(5):516-21.Full text Abstract
16. Murdoch DL, O'Neill K, Jackson J, et al. Are atrial fibrillation guidelines altering management? A community based study. Scott Med J. 2005 Nov;50(4):166-9. Abstract
17. Wang L, Ze F, Li J, et al. Trends of global burden of atrial fibrillation/flutter from Global Burden of Disease Study 2017. Heart. 2021 Jun;107(11):881-7.Full text Abstract
18. Colilla S, Crow A, Petkun W, et al. Estimates of current and future incidence and prevalence of atrial fibrillation in the U.S. adult population. Am J Cardiol. 2013 Oct 15;112(8):1142-7.Full text Abstract
19. Captur G, Arbustini E, Bonne G, et al. Lamin and the heart. Heart. 2018 Mar;104(6):468-479.Full text Abstract
20. Garrey WE. Auricular fibrillation. Physiol Rev. 1924 Apr;4(2):215-50.
21. Moe GK, Rheinboldt WC, Abildskov JA. A computer model of atrial fibrillation. Am Heart J. 1964 Feb;67:200-20. Abstract
22. Allessie MA, Bonke FI, Schopman FJ. Circus movement in rabbit atrial muscle as a mechanism of tachycardia. III. The "leading circle" concept: a new model of circus movement in cardiac tissue without the involvement of an anatomical obstacle. Circ Res. 1977 Jul;41(1):9-18.Full text Abstract
23. Nattel S, Shiroshita-Takeshita A, Brundel BJ, et al. Mechanisms of atrial fibrillation: lessons from animal models. Prog Cardiovasc Dis. 2005 Jul-Aug;48(1):9-28. Abstract
24. Cheung DW. Pulmonary vein as an ectopic focus in digitalis-induced arrhythmia. Nature. 1981 Dec 10;294(5841):582-4. Abstract
25. Cheung DW. Electrical activity of the pulmonary vein and its interaction with the right atrium in the guinea-pig. J Physiol. 1981 May;314:445-56.Full text Abstract
26. Haissaguerre M, Jais P, Shah DC, et al. Spontaneous initiation of atrial fibrillation by ectopic beats originating in the pulmonary veins. N Engl J Med. 1998 Sep 3;339(10):659-66.Full text Abstract
27. Allessie MA, Boyden PA, Camm AJ, et al. Pathophysiology and prevention of atrial fibrillation. Circulation. 2001 Feb 6;103(5):769-77.Full text Abstract
28. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of atrial fibrillation: the Framingham Study. N Engl J Med. 1982 Apr 29;306(17):1018-22. Abstract
29. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham heart study. JAMA. 1994 Mar 16;271(11):840-4. Abstract
30. Aune D, Mahamat-Saleh Y, Kobeissi E, et al. Blood pressure, hypertension and the risk of atrial fibrillation: a systematic review and meta-analysis of cohort studies. Eur J Epidemiol. 2023 Feb;38(2):145-78.Full text Abstract
31. Lokshyn S, Mewis C, Kuhlkamp V. Atrial fibrillation in coronary artery disease. Int J Cardiol. 2000 Jan 15;72(2):133-6. Abstract
32. Chugh SS, Blackshear JL, Shen WK, et al. Epidemiology and natural history of atrial fibrillation: clinical implications. J Am Coll Cardiol. 2001 Feb;37(2):371-8.Full text Abstract
33. Kannel WB, Abbott RD, Savage DD, et al. Coronary heart disease and atrial fibrillation: the Framingham Study. Am Heart J. 1983 Aug;106(2):389-96. Abstract
34. Xu J, Sun Y, Gong D, et al. Impact of preexisting diabetes mellitus on cardiovascular and all-cause mortality in patients with atrial fibrillation: a meta-analysis. Front Endocrinol (Lausanne). 2022;13:921159.Full text Abstract
35. Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation. 2005 Sep 20;112(12):1736-42.Full text Abstract
36. Csengeri D, Sprünker NA, Di Castelnuovo A, et al. Alcohol consumption, cardiac biomarkers, and risk of atrial fibrillation and adverse outcomes. Eur Heart J. 2021 Mar 21;42(12):1170-7.Full text Abstract
37. Gallagher C, Hendriks JML, Elliott AD, et al. Alcohol and incident atrial fibrillation: a systematic review and meta-analysis. Int J Cardiol. 2017 Nov 1;246:46-52. Abstract
38. Marcus GM, Vittinghoff E, Whitman IR, et al. Acute consumption of alcohol and discrete atrial fibrillation events. Ann Intern Med. 2021 Nov;174(11):1503-9. Abstract
39. Tu SJ, Gallagher C, Elliott AD, et al. Risk thresholds for total and beverage-specific alcohol consumption and incident atrial fibrillation. JACC Clin Electrophysiol. 2021 Dec;7(12):1561-9. Abstract
40. Koskinen P, Kupari M, Leinonen H. Role of alcohol in the recurrence of atrial fibrillation in persons less than 65 years of age. Am J Cardiol. 1990 Oct 15;66(12):954-8. Abstract
41. Rich EC, Siebold C, Campion B. Alcohol-related acute atrial fibrillation: a case control study and review of 40 patients. Arch Intern Med. 1985 May;145(5):830-3. Abstract
42. Chamberlain AM, Agarwal SK, Folsom AR, et al. Smoking and incidence of atrial fibrillation: results from the Atherosclerosis Risk in Communities (ARIC) Study. Heart Rhythm. 2011 Aug;8(8):1160-6.Full text Abstract
43. Aune D, Sen A, Schlesinger S, et al. Body mass index, abdominal fatness, fat mass and the risk of atrial fibrillation: a systematic review and dose-response meta-analysis of prospective studies. Eur J Epidemiol. 2017 Mar;32(3):181-92.Full text Abstract
44. Powell-Wiley TM, Poirier P, Burke LE, et al. Obesity and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 May 25;143(21):e984-1010.Full text Abstract
45. Mehra R, Chung MK, Olshansky B, et al. Sleep-disordered breathing and cardiac arrhythmias in adults: mechanistic insights and clinical implications: a scientific statement from the American Heart Association. Circulation. 2022 Aug 30;146(9):e119-36.Full text Abstract
46. Stevenson IH, Teichtahl H, Cunnington D, et al. Prevalence of sleep disordered breathing in paroxysmal and persistent atrial fibrillation patients with normal left ventricular function. Eur Heart J. 2008 Jul;29(13):1662-9.Full text Abstract
47. Yeghiazarians Y, Jneid H, Tietjens JR, et al. Obstructive sleep apnea and cardiovascular disease: a scientific statement from the American Heart Association. Circulation. 2021 Jul 20;144(3):e56-67.Full text Abstract
48. Linz D, Brooks AG, Elliott AD, et al. Variability of sleep apnea severity and risk of atrial fibrillation: The VARIOSA-AF Study. JACC Clin Electrophysiol. 2019 Jun;5(6):692-701.Full text Abstract
49. Congrete S, Bintvihok M, Thongprayoon C, et al. Effect of obstructive sleep apnea and its treatment of atrial fibrillation recurrence after radiofrequency catheter ablation: a meta-analysis. J Evid Based Med. 2018 Aug;11(3):145-51. Abstract
50. Chung MK, Eckhardt LL, Chen LY, et al. Lifestyle and risk factor modification for reduction of atrial fibrillation: a scientific statement from the American Heart Association. Circulation. 2020 Apr 21;141(16):e750-72.Full text Abstract
51. Flynn RW, Bonellie SR, Jung RT, et al. Serum thyroid-stimulating hormone concentration and morbidity from cardiovascular disease and fractures in patients on long-term thyroxine therapy. J Clin Endocrinol Metab. 2010 Jan;95(1):186-93. Abstract
52. Lip GY, Beevers DG, Singh SP, et al. ABC of atrial fibrillation: aetiology, pathophysiology, and clinical features. BMJ. 1995 Nov 25;311(7017):1425-8.Full text Abstract
53. Toft AD. Clinical practice: subclinical hyperthyroidism. N Engl J Med. 2001 Aug 16;345(7):512-6. Abstract
54. Huang M, Yang S, Ge G, et al. Effects of thyroid dysfunction and the thyroid-stimulating hormone levels on the risk of atrial fibrillation: a systematic review and dose-response meta-analysis from cohort studies. Endocr Pract. 2022 Aug;28(8):822-31. Abstract
55. Wang J, Liu L, Feng J, et al. Regional and functional factors determining induction and maintenance of atrial fibrillation in dogs. Am J Physiol. 1996 Jul;271(1 Pt 2):H148-58. Abstract
56. Coumel P. Autonomic influences in atrial tachyarrhythmias. J Cardiovasc Electrophysiol. 1996 Oct;7(10):999-1007. Abstract
57. Pappone C, Santinelli V, Manguso F, et al. Pulmonary vein denervation enhances long-term benefit after circumferential ablation for paroxysmal atrial fibrillation. Circulation. 2004 Jan 27;109(3):327-34.Full text Abstract
58. Lyon AR, López-Fernández T, Couch LS, et al. 2022 ESC guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS). Eur Heart J. 2022 Nov 1;43(41):4229-361.Full text Abstract
59. Potter AS, Hulsurkar MM, Wu L, et al. Kinase inhibitors and atrial fibrillation: mechanisms of action and clinical implications. JACC Clin Electrophysiol. 2023 Apr;9(4):591-602.Full text Abstract
60. Kivimäki M, Nyberg ST, Batty GD, et al. Long working hours as a risk factor for atrial fibrillation: a multi-cohort study. Eur Heart J. 2017 Sep 7;38(34):2621-8.Full text Abstract
61. Elliott AD, Linz D, Mishima R, et al. Association between physical activity and risk of incident arrhythmias in 402 406 individuals: evidence from the UK Biobank cohort. Eur Heart J. 2020 Apr 14;41(15):1479-86.Full text Abstract
62. Levin MG, Judy R, Gill D, et al. Genetics of height and risk of atrial fibrillation: A Mendelian randomization study. PLoS Med. 2020 Oct;17(10):e1003288.Full text Abstract
63. Marott JL, Skielboe AK, Dixen U, et al. Increasing population height and risk of incident atrial fibrillation: the Copenhagen City Heart Study. Eur Heart J. 2018 Dec 1;39(45):4012-9.Full text Abstract
64. Chen M, Zhao J, Zhuo C, et al. The Association Between Ambient Air Pollution and Atrial Fibrillation. Int Heart J. 2021 Mar 30;62(2):290-297.Full text Abstract
65. Yue C, Yang F, Li F, et al. Association between air pollutants and atrial fibrillation in general population: a systematic review and meta-analysis. Ecotoxicol Environ Saf. 2021 Jan 15;208:111508.Full text Abstract
66. Scutelnic A, Mattle HP, Branca M, et al. Migraine and atrial fibrillation: a systematic review. Eur J Neurol. 2022 Mar;29(3):910-20.Full text Abstract
67. Healey JS, Baranchuk A, Crystal E, et al. Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis. J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9. Abstract
68. Wachtell K, Lehto M, Gerdts E, et al. Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol. 2005 Mar 1;45(5):712-9. Abstract
69. Olsson LG, Swedberg K, Ducharme A, et al. Atrial fibrillation and risk of clinical events in chronic heart failure with and without left ventricular systolic dysfunction: results from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) program. J Am Coll Cardiol. 2006 May 16;47(10):1997-2004.Full text Abstract
70. Young-Xu Y, Jabbour S, Goldberg R, et al. Usefulness of statin drugs in protecting against atrial fibrillation in patients with coronary artery disease. Am J Cardiol. 2003 Dec 15;92(12):1379-83. Abstract
71. Siu CW, Lau CP, Tse HF. Prevention of atrial fibrillation recurrence by statin therapy in patients with lone atrial fibrillation after successful cardioversion. Am J Cardiol. 2003 Dec 1;92(11):1343-5. Abstract
72. Mozaffarian D, Psaty BM, Rimm EB, et al. Fish intake and risk of incident atrial fibrillation. Circulation. 2004 Jul 27;110(4):368-73.Full text Abstract
73. Arsenault KA, Yusuf AM, Crystal E, et al. Interventions for preventing post-operative atrial fibrillation in patients undergoing heart surgery. Cochrane Database Syst Rev. 2013 Jan 31;2013(1):CD003611.Full text Abstract
74. Mishima RS, Verdicchio CV, Noubiap JJ, et al. Self-reported physical activity and atrial fibrillation risk: a systematic review and meta-analysis. Heart Rhythm. 2021 Apr;18(4):520-8.Full text Abstract
75. National Institute for Health and Care Excellence. Atrial fibrillation: diagnosis and management. Jun 2021 [internet publication].Full text
76. Jurgens CY, Lee CS, Aycock DM, et al. State of the science: the relevance of symptoms in cardiovascular disease and research: a scientific statement from the American Heart Association. Circulation. 2022 Sep 20;146(12):e173-84.Full text Abstract
77. Chen LY, Norby FL, Gottesman RF, et al. Association of atrial fibrillation with cognitive decline and dementia over 20 Years: the ARIC-NCS (Atherosclerosis Risk in Communities Neurocognitive Study). J Am Heart Assoc. 2018 Mar 7;7(6):e007301.Full text Abstract
78. Papanastasiou CA, Theochari CA, Zareifopoulos N, et al. Atrial fibrillation is associated with cognitive impairment, all-cause dementia, vascular dementia, and alzheimer's disease: a systematic review and meta-analysis. J Gen Intern Med. 2021 Oct;36(10):3122-35.Full text Abstract
79. Koh YH, Lew LZW, Franke KB, et al. Predictive role of atrial fibrillation in cognitive decline: a systematic review and meta-analysis of 2.8 million individuals. Europace. 2022 Sep 1;24(8):1229-39.Full text Abstract
80. Zhang W, Liang J, Li C, et al. Age at diagnosis of atrial fibrillation and incident dementia.. JAMA Netw Open. 2023 Nov 1;6(11):e2342744.Full text Abstract
81. Diener HC, Hart RG, Koudstaal PJ, et al. Atrial fibrillation and cognitive function: JACC review topic of the week. J Am Coll Cardiol. 2019 Feb 12;73(5):612-19.Full text Abstract
82. Lopez Perales CR, Van Spall HGC, Maeda S, et al. Mobile health applications for the detection of atrial fibrillation: a systematic review. Europace. 2021 Jan 27;23(1):11-28.Full text Abstract
83. Guo Y, Wang H, Zhang H, et al. Mobile Photoplethysmographic Technology to Detect Atrial Fibrillation. J Am Coll Cardiol. 2019 Nov 12;74(19):2365-2375.Full text Abstract
84. Nazarian S, Lam K, Darzi A, et al. Diagnostic accuracy of smartwatches for the detection of cardiac arrhythmia: systematic review and meta-analysis. J Med Internet Res. 2021 Aug 27;23(8):e28974.Full text Abstract
85. Gill S, Bunting KV, Sartini C, et al. Smartphone detection of atrial fibrillation using photoplethysmography: a systematic review and meta-analysis. Heart. 2022 Sep 26;108(20):1600-7.Full text Abstract
86. Sattar Y, Song D, Sarvepalli D, et al. Accuracy of pulsatile photoplethysmography applications or handheld devices vs. 12-lead ECG for atrial fibrillation screening: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2022 Oct;65(1):33-44.Full text Abstract
87. Biersteker TE, Schalij MJ, Treskes RW. Impact of mobile health devices for the detection of atrial fibrillation: systematic review. JMIR Mhealth Uhealth. 2021 Apr 28;9(4):e26161.Full text Abstract
88. Malik V, Gallagher C, Linz D, et al. Atrial fibrillation is associated with syncope and falls in older adults: a systematic review and meta-analysis. Mayo Clin Proc. 2020 Apr;95(4):676-87.Full text Abstract
89. Gladstone DJ, Spring M, Dorian P, et al. Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med. 2014 Jun 26;370(26):2467-77.Full text Abstract
90. Sanna T, Diener HC, Passman RS, et al. Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med. 2014 Jun 26;370(26):2478-86.Full text Abstract
91. US Preventive Services Task Force. Final recommendation statement. Atrial fibrillation: screening. 25 January 2022 [internet publication].Full text
92. Gillis AM, Morck M. Atrial fibrillation after DDDR pacemaker implantation. J Cardiovasc Electrophysiol. 2002 Jun;13(6):542-7. Abstract
93. Lip GYH. The ABC pathway: an integrated approach to improve AF management. Nat Rev Cardiol. 2017 Nov;14(11):627-8.Full text Abstract
94. Lip GY, Nieuwlaat R, Pisters R, et al. Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest. 2010 Feb;137(2):263-72. Abstract
95. Brønnum Nielsen P, Larsen TB, Gorst-Rasmussen A, et al. Intracranial hemorrhage and subsequent ischemic stroke in patients with atrial fibrillation: a nationwide cohort study. Chest. 2015 Jun;147(6):1651-8. Abstract
96. Aggarwal R, Ruff CT, Virdone S, et al. Development and validation of the DOAC score: a novel bleeding risk prediction tool for patients with atrial fibrillation on direct-acting oral anticoagulants. Circulation. 2023 Sep 19;148(12):936-46.Full text Abstract
97. Rohla M, Weiss TW, Pecen L, et al. Risk factors for thromboembolic and bleeding events in anticoagulated patients with atrial fibrillation: the prospective, multicentre observational PREvention oF thromboembolic events - European Registry in Atrial Fibrillation (PREFER in AF). BMJ Open. 2019 Mar 30;9(3):e022478.Full text Abstract
98. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014 Mar 15;383(9921):955-62. Abstract
99. Connolly SJ, Ezekowitz MD, Yusuf S, et al; RE-LY Steering Committee and Investigators. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med. 2009 Sep 17;361(12):1139-51.Full text Abstract
100. Patel MR, Mahaffey KW, Garg J, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011 Sep 8;365(10):883-91.Full text Abstract
101. Halperin JL, Hankey GJ, Wojdyla DM, et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily, Oral, Direct Factor Xa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF). Circulation. 2014 Jul 8;130(2):138-46.Full text Abstract
102. Granger CB, Alexander JH, McMurray JJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011 Sep 15;365(11):981-92.Full text Abstract
103. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013 Nov 28;369(22):2093-104.Full text Abstract
104. Miller CS, Grandi SM, Shimony A, et al. Meta-analysis of efficacy and safety of new oral anticoagulants (dabigatran, rivaroxaban, apixaban) versus warfarin in patients with atrial fibrillation. Am J Cardiol. 2012 Aug 1;110(3):453-60. Abstract
105. Caldeira D, Rodrigues FB, Barra M, et al. Non-vitamin K antagonist oral anticoagulants and major bleeding-related fatality in patients with atrial fibrillation and venous thromboembolism: a systematic review and meta-analysis. Heart. 2015 Aug;101(15):1204-11. Abstract
106. Carnicelli AP, Hong H, Connolly SJ, et al. Direct oral anticoagulants versus warfarin in patients with atrial fibrillation: patient-level network meta-analyses of randomized clinical trials with interaction testing by age and sex. Circulation. 2022 Jan 25;145(4):242-55.Full text Abstract
107. Fong KY, Chan YH, Yeo C, et al. Systematic review and meta-analysis of direct oral anticoagulants versus warfarin in atrial fibrillation with low stroke risk. Am J Cardiol. 2023 Oct 1;204:366-76. Abstract
108. Suppah M, Kamal A, Saadoun R, et al. An evidence-based approach to anticoagulation therapy comparing direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and bioprosthetic valves: a systematic review, meta-analysis, and network meta-analysis. Am J Cardiol. 2023 Nov 1;206:132-50. Abstract
109. Sharma M, Cornelius VR, Patel JP, et al. Efficacy and harms of direct oral anticoagulants in the elderly for stroke prevention in atrial fibrillation and secondary prevention of venous thromboembolism: systematic review and meta-analysis. Circulation. 2015 Jul 21;132(3):194-204.Full text Abstract
110. Del-Carpio Munoz F, Gharacholou SM, Munger TM, et al. Meta-analysis of renal function on the safety and efficacy of novel oral anticoagulants for atrial fibrillation. Am J Cardiol. 2016 Jan 1;117(1):69-75. Abstract
111. Gallego P, Roldán V, Marin F, et al. SAMe-TT2R2 score, time in therapeutic range, and outcomes in anticoagulated patients with atrial fibrillation. Am J Med. 2014 Nov;127(11):1083-8.Full text Abstract
112. Lip GY, Haguenoer K, Saint-Etienne C, et al. Relationship of the SAMe-TT₂R₂ score to poor-quality anticoagulation, stroke, clinically relevant bleeding, and mortality in patients with atrial fibrillation. Chest. 2014 Sep;146(3):719-26. Abstract
113. Friberg L, Andersson T, Rosenqvist M. Less dementia and stroke in low-risk patients with atrial fibrillation taking oral anticoagulation. Eur Heart J. 2019 Jul 21;40(28):2327-35.Full text Abstract
114. Cheng W, Liu W, Li B, et al. Relationship of anticoagulant therapy with cognitive impairment among patients with atrial fibrillation: a meta-analysis and systematic review. J Cardiovasc Pharmacol. 2018 Jun;71(6):380-7. Abstract
115. Kantharia BK. Impact of catheter ablation of atrial fibrillation on reduction of the risks of dementia and hospitalization. Int J Cardiol. 2020 Apr 1;304:47-9. Abstract
116. Glikson M, Wolff R, Hindricks G, et al. EHRA/EAPCI expert consensus statement on catheter-based left atrial appendage occlusion - an update. Europace. 2020 Feb 1;22(2):184.Full text Abstract
117. Saw J, Holmes DR, Cavalcante JL, et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. 2023 May;20(5):e1-16.Full text Abstract
118. Holmes DR, Reddy VY, Turi ZG, et al; PROTECT AF Investigators. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet. 2009 Aug 15;374(9689):534-42. Abstract
119. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. Catheter Cardiovasc Interv. 2011 Apr 1;77(5):700-6. Abstract
120. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. J Am Coll Cardiol. 2013 Jul 9;62(2):108-18.Full text Abstract
121. Kar S, Doshi SK, Sadhu A, et al. Primary outcome evaluation of a next-generation left atrial appendage closure device: results from the PINNACLE FLX Trial. Circulation. 2021 May 4;143(18):1754-62.Full text Abstract
122. Whitlock RP, Belley-Cote EP, Paparella D, et al. LAAOS III Investigators. Left atrial appendage occlusion during cardiac surgery to prevent stroke. N Engl J Med. 2021 Jun 3;384(22):2081-91.Full text Abstract
123. Chew DS, Zhou K, Pokorney SD, et al. Left atrial appendage occlusion versus oral anticoagulation in atrial fibrillation : a decision analysis. Ann Intern Med. 2022 Sep;175(9):1230-9. Abstract
124. Kantharia BK. Left atrial appendage occlusion versus anticoagulation in atrial fibrillation: equipoise when bleeding risk is high. Ann Intern Med. 2022 Sep;175(9):1330-1. Abstract
125. Bressler R, Bahl JJ. Principles of drug therapy for the elderly patient. Mayo Clin Proc. 2003 Dec;78(12):1564-77. Abstract
126. Opie LH. Adverse cardiovascular drug interactions. Curr Probl Cardiol. 2000 Sep;25(9):621-76. Abstract
127. Roden DM. Antiarrhythmic drugs: from mechanisms to clinical practice. Heart. 2000 Sep;84(3):339-46.Full text Abstract
128. Friedman PL, Stevenson WG. Proarrhythmia. Am J Cardiol. 1998 Oct 16;82(8A):50N-8N. Abstract
129. Lopes RD, Rordorf R, De Ferrari GM, et al. Digoxin and mortality in patients with atrial fibrillation. J Am Coll Cardiol. 2018 Mar 13;71(10):1063-74.Full text Abstract
130. Kay GN, Ellenbogen KA, Giudici M, et al. The Ablate and Pace Trial: a prospective study of catheter ablation of the AV conduction system and permanent pacemaker implantation for treatment of atrial fibrillation. APT Investigators. J Interv Card Electrophysiol. 1998 Jun;2(2):121-35. Abstract
131. Ganesan AN, Brooks AG, Roberts-Thomson KC, et al. Role of AV nodal ablation in cardiac resynchronization in patients with coexistent atrial fibrillation and heart failure a systematic review. J Am Coll Cardiol. 2012 Feb 21;59(8):719-26.Full text Abstract
132. Brignole M, Pentimalli F, Palmisano P, et al. AV junction ablation and cardiac resynchronization for patients with permanent atrial fibrillation and narrow QRS: the APAF-CRT mortality trial. Eur Heart J. 2021 Dec 7;42(46):4731-9.Full text Abstract
133. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2022 May 3;145(18):e895-1032.Full text Abstract
134. Al-Khatib SM, Allen LaPointe NM, Chatterjee R, et al. Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med. 2014 Jun 3;160(11):760-73.Full text Abstract
135. Kirchhof P, Camm AJ, Goette A, et al. Early rhythm-control therapy in patients with atrial fibrillation. N Engl J Med. 2020 Oct 1;383(14):1305-16.Full text Abstract
136. Rillig A, Borof K, Breithardt G, et al. Early rhythm control in patients with atrial fibrillation and high comorbidity burden.. Circulation. 2022 Sep 13;146(11):836-47.Full text Abstract
137. Kim D, Yang PS, You SC, et al. Early rhythm control therapy for atrial fibrillation in low-risk patients : a nationwide propensity score-weighted study. Ann Intern Med. 2022 Oct;175(10):1356-65.Full text Abstract
138. Zhu W, Wu Z, Dong Y, et al. Effectiveness of early rhythm control in improving clinical outcomes in patients with atrial fibrillation: a systematic review and meta-analysis. BMC Med. 2022 Oct 13;20(1):340.Full text Abstract
139. Eckardt L, Sehner S, Suling A, et al. Attaining sinus rhythm mediates improved outcome with early rhythm control therapy of atrial fibrillation: the EAST-AFNET 4 trial. Eur Heart J. 2022 Oct 21;43(40):4127-44.Full text Abstract
140. Lip GY, Gitt AK, Le Heuzey JY, et al. Overtreatment and undertreatment with anticoagulation in relation to cardioversion of atrial fibrillation (the RHYTHM-AF study). Am J Cardiol. 2014 Feb 1;113(3):480-4. Abstract
141. Airaksinen KE, Grönberg T, Nuotio I, et al. Thromboembolic complications after cardioversion of acute atrial fibrillation: the FinCV (Finnish CardioVersion) study. J Am Coll Cardiol. 2013 Sep 24;62(13):1187-92.Full text Abstract
142. Vos MA, Golitsyn SR, Stangl K, et al; Ibutilide/Sotalol Comparator Study Group. Superiority of ibutilide (a new class III agent) over DL-sotalol in converting atrial flutter and atrial fibrillation. Heart. 1998 Jun;79(6):568-75.Full text Abstract
143. Oral H, Souza JJ, Michaud GF, et al. Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med. 1999 Jun 17;340(24):1849-54.Full text Abstract
144. Li H, Natale A, Tomassoni G, et al. Usefulness of ibutilide in facilitating successful external cardioversion of refractory atrial fibrillation. Am J Cardiol. 1999 Nov 1;84(9):1096-8;A10. Abstract
145. Singh BN, Connolly SJ, Crijns HJ, et al. Dronedarone for maintenance of sinus rhythm in atrial fibrillation or flutter. N Engl J Med. 2007 Sep 6;357(10):987-99.Full text Abstract
146. Le Heuzey J, De Ferrari GM, Radzik D, et al. A short-term, randomized, double-blind, parallel-group study to evaluate the efficacy and safety of dronedarone versus amiodarone in patients with persistent atrial fibrillation: the DIONYSOS study. J Cardiovasc Electrophysiol. 2010 Jun 1;21(6):597-605. Abstract
147. Køber L, Torp-Pedersen C, McMurray JJ, et al; Dronedarone Study Group. Increased mortality after dronedarone therapy for severe heart failure. N Engl J Med. 2008 Jun 19;358(25):2678-87.Full text Abstract
148. Hohnloser SH, Crijns HJ, van Eickels M, et al. Effect of dronedarone on cardiovascular events in atrial fibrillation. N Engl J Med. 2009 Feb 12;360(7):668-78.Full text Abstract
149. U.S. Food and Drug Administration. FDA Drug Safety Communication: review update of Multaq (dronedarone) and increased risk of death and serious cardiovascular adverse events. Jul 2011 [internet publication].Full text
150. Valembois L, Audureau E, Takeda A, et al. Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev. 2019 Sep 4;(9):CD005049.Full text Abstract
151. Calkins H, Hindricks G, Cappato R, et al. 2017 HRS/EHRA/ECAS/APHRS/SOLAECE expert consensus statement on catheter and surgical ablation of atrial fibrillation. Europace. 2018 Jan 1;20(1):e1-160.Full text Abstract
152. Kuck KH, Brugada J, Furnkranz A, et al; FIRE AND ICE Investigators. Cryoballoon or radiofrequency ablation for paroxysmal atrial fibrillation. N Engl J Med. 2016 Jun 9;374(23):2235-45.Full text Abstract
153. Luik A, Radzewtiz A, Kieser M, et al. Cryoballoon versus open irrigated radiofrequency ablation in patients with paroxysmal atrial fibrillation: the prospective, randomized, controlled, noninferiority FreezeAF Study. Circulation. 2015 Oct 6;132(14):1311-9.Full text Abstract
154. Morillo CA, Verma A, Connolly SJ, et al. Radiofrequency ablation vs antiarrhythmic drugs as first-line treatment of paroxysmal atrial fibrillation (RAAFT-2): a randomized trial. JAMA. 2014 Feb 19;311(7):692-700.Full text Abstract
155. Jons C, Hansen PS, Johannessen A, et al. The Medical ANtiarrhythmic Treatment or Radiofrequency Ablation in Paroxysmal Atrial Fibrillation (MANTRA-PAF) trial: clinical rationale, study design, and implementation. Europace. 2009 Jul;11(7):917-23.Full text Abstract
156. Andrade JG, Deyell MW, Macle L, et al. Progression of atrial fibrillation after cryoablation or drug therapy. N Engl J Med. 2023 Jan 12;388(2):105-16.Full text Abstract
157. Mark DB, Anstrom KJ, Sheng S, et al. Effect of catheter ablation vs medical therapy on quality of life among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019 Apr 2;321(13):1275-85.Full text Abstract
158. Packer DL, Mark DB, Robb RA, et al. Effect of catheter ablation vs antiarrhythmic drug therapy on mortality, stroke, bleeding, and cardiac arrest among patients with atrial fibrillation: the CABANA randomized clinical trial. JAMA. 2019 Apr 2;321(13):1261-74.Full text Abstract
159. Packer DL, Piccini JP, Monahan KH, et al. Ablation versus drug therapy for atrial fibrillation in heart failure: results from the CABANA trial. Circulation. 2021 Apr 6;143(14):1377-90.Full text Abstract
160. Marrouche NF, Brachmann J, Andresen D, et al. Catheter ablation for atrial fibrillation with heart failure. N Engl J Med. 2018 Feb; 378(5):417-27.Full text Abstract
161. Briceño DF, Markman TM, Lupercio F, et al. Catheter ablation versus conventional treatment of atrial fibrillation in patients with heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. J Interv Card Electrophysiol. 2018 Oct;53(1):19-29. Abstract
162. Elgendy AY, Mahmoud AN, Khan MS, et al. Meta-analysis comparing catheter-guided ablation versus conventional medical therapy for patients with atrial fibrillation and heart failure with reduced ejection fraction. Am J Cardiol. 2018 Sep 1;122(5):806-13. Abstract
163. AlTurki A, Proietti R, Dawas A, et al. Catheter ablation for atrial fibrillation in heart failure with reduced ejection fraction: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord. 2019 Jan 15;19(1):18.Full text Abstract
164. Ahn J, Kim HJ, Choe JC, et al. Treatment strategies for atrial fibrillation with left ventricular systolic dysfunction - meta-analysis. Circ J. 2018 Jun 25;82(7):1770-7.Full text Abstract
165. Chen S, Pürerfellner H, Meyer C, et al. Rhythm control for patients with atrial fibrillation complicated with heart failure in the contemporary era of catheter ablation: a stratified pooled analysis of randomized data. Eur Heart J. 2020 Aug 7;41(30):2863-73.Full text Abstract
166. Sohns C, Fox H, Marrouche NF, et al. Catheter ablation in end-stage heart failure with atrial fibrillation. N Engl J Med. 2023 Oct 12;389(15):1380-9.Full text Abstract
167. Gopinathannair R, Chen LY, Chung MK, et al. Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association. Circ Arrhythm Electrophysiol. 2021 Jun;14(6):HAE0000000000000078.Full text Abstract
168. Kantharia BK. Heart failure and atrial fibrillation: is atrial fibrillation ablation in heart failure pointless or mandatory? J Cardiovasc Electrophysiol. 2024 Mar;35(3):530-7.Full text Abstract
169. Gillinov AM, Gelijns AC, Parides MK, et al. Surgical ablation of atrial fibrillation during mitral-valve surgery. N Engl J Med. 2015 Apr 9;372(15):1399-409.Full text Abstract
170. Phan K, Xie A, La Meir M, et al. Surgical ablation for treatment of atrial fibrillation in cardiac surgery: a cumulative meta-analysis of randomised controlled trials. Heart. 2014 May;100(9):722-30. Abstract
171. Damiano RJ Jr, Gaynor SL, Bailey M, et al. The long-term outcome of patients with coronary disease and atrial fibrillation undergoing the Cox maze procedure. J Thorac Cardiovasc Surg. 2003 Dec;126(6):2016-21. Abstract
172. Melby SJ, Kaiser SP, Bailey MS, et al. Surgical treatment of atrial fibrillation with bipolar radiofrequency ablation: mid-term results in one hundred consecutive patients. J Cardiovasc Surg (Torino). 2006 Dec;47(6):705-10. Abstract
173. DeLurgio DB, Crossen KJ, Gill J, et al. Hybrid convergent procedure for the treatment of persistent and long-standing persistent atrial fibrillation: results of CONVERGE clinical trial. Circ Arrhythm Electrophysiol. 2020 Dec;13(12):e009288.Full text Abstract
174. Steinberg BA, Li Z, O'Brien EC, et al. Atrial fibrillation burden and heart failure: Data from 39,710 individuals with cardiac implanted electronic devices. Heart Rhythm. 2021 May;18(5):709-16. Abstract
175. Chew DS, Li Z, Steinberg BA, et al. Arrhythmic burden and the risk of cardiovascular outcomes in patients with paroxysmal atrial fibrillation and cardiac implanted electronic devices. Circ Arrhythm Electrophysiol. 2022 Feb;15(2):e010304.Full text Abstract
176. Andrade JG, Deyell MW, Macle L, et al. Healthcare utilization and quality of life for atrial fibrillation burden: the CIRCA-DOSE study. Eur Heart J. 2023 Mar 1;44(9):765-76.Full text Abstract
177. Benz AP, Hijazi Z, Lindbäck J, et al. Biomarker-based risk prediction with the ABC-AF scores in patients with atrial fibrillation not receiving oral anticoagulation. Circulation. 2021 May 11;143(19):1863-73.Full text Abstract
178. Perez MV, Mahaffey KW, Hedlin H, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. N Engl J Med. 2019 Nov 14;381(20):1909-17.Full text Abstract
179. Li F, Sun JY, Wu LD, et al. The long-term outcomes of ablation with vein of Marshall ethanol infusion vs. ablation alone in patients with atrial fibrillation: a meta-analysis. Front Cardiovasc Med. 2022;9:871654.Full text Abstract
180. Holmqvist F, Kim S, Steinberg BA, et al. Heart rate is associated with progression of atrial fibrillation, independent of rhythm. Heart. 2015 Jun;101(11):894-9.Full text Abstract
181. Batra G, Svennblad B, Held C, et al. All types of atrial fibrillation in the setting of myocardial infarction are associated with impaired outcome. Heart. 2016 Jun 15;102(12):926-33. Abstract
182. Krahn AD, Manfreda J, Tate RB, et al. The natural history of atrial fibrillation: incidence, risk factors, and prognosis in the Manitoba Follow-Up Study. Am J Med. 1995 May;98(5):476-84. Abstract
183. Benjamin EJ, Wolf PA, D'Agostino RB, et al. Impact of atrial fibrillation on the risk of death: the Framingham Heart Study. Circulation. 1998 Sep 8;98(10):946-52.Full text Abstract
184. Cooper HA, Bloomfield DA, Bush DE, et al. Relation between achieved heart rate and outcomes in patients with atrial fibrillation (from the Atrial Fibrillation Follow-up Investigation of Rhythm Management [AFFIRM] Study). Am J Cardiol. 2004 May 15;93(10):1247-53. Abstract
185. Hagens VE, Ranchor AV, Van Sonderen E, et al. Effect of rate or rhythm control on quality of life in persistent atrial fibrillation: results from the Rate Control Versus Electrical Cardioversion (RACE) Study. J Am Coll Cardiol. 2004 Jan 21;43(2):241-7. Abstract
186. Pappone C, Rosanio S, Augello G, et al. Mortality, morbidity, and quality of life after circumferential pulmonary vein ablation for atrial fibrillation: outcomes from a controlled nonrandomized long-term study. J Am Coll Cardiol. 2003 Jul 16;42(2):185-97.Full text Abstract
187. Pawar PP, Jones LG, Feller M, et al. Association between smoking and outcomes in older adults with atrial fibrillation. Arch Gerontol Geriatr. 2012 Jul-Aug;55(1):85-90.Full text Abstract
188. Gage BF, Waterman AD, Shannon W, et al. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA. 2001 Jun 13;285(22):2864-70.Full text Abstract
189. Yoshimoto T, Toyoda K, Ihara M, et al. Impact of previous stroke on clinical outcome in elderly patients with nonvalvular atrial fibrillation: ANAFIE registry. Stroke. 2022 Aug;53(8):2549-58.Full text Abstract
190. Benz AP, Hohnloser SH, Eikelboom JW, et al. Outcomes of patients with atrial fibrillation and ischemic stroke while on oral anticoagulation. Eur Heart J. 2023 May 21;44(20):1807-14.Full text Abstract
191. Lip GY, Lim HS. Atrial fibrillation and stroke prevention. Lancet Neurol. 2007 Nov;6(11):981-93. Abstract
192. Hylek EM, Evans-Molina C, Shea C, et al. Major hemorrhage and tolerability of warfarin in the first year of therapy among elderly patients with atrial fibrillation. Circulation. 2007 May 29;115(21):2689-96.Full text Abstract
193. Mant J, Hobbs, R, Fletcher K, et al. Warfarin versus aspirin for stroke prevention in an elderly community population with atrial fibrillation (the Birmingham Atrial Fibrillation Treatment of the Aged Study, BAFTA): a randomised controlled trial. Lancet. 2007 Aug 11;370(9586):493-503. Abstract
194. Adderley NJ, Nirantharakumar K, Marshall T. Risk of stroke and transient ischaemic attack in patients with a diagnosis of resolved atrial fibrillation: retrospective cohort studies. BMJ. 2018 May 9;361:k1717.Full text Abstract
195. Cappato R, Calkins H, Chen SA, et al. Worldwide survey on the methods, efficacy, and safety of catheter ablation for human atrial fibrillation. Circulation. 2005 Mar 8;111(9):1100-5.Full text Abstract
196. Cappato R, Calkins H, Chen SA, et al. Prevalence and causes of fatal outcome in catheter ablation of atrial fibrillation. J Am Coll Cardiol. 2009 May 12;53(19):1798-803.Full text Abstract
197. Grindal AW, Sparrow RT, McIntyre WF, et al. Alcohol consumption and atrial arrhythmia recurrence after atrial fibrillation ablation: a systematic review and meta-analysis. Can J Cardiol. 2023 Mar;39(3):266-73. Abstract
198. Park DY, An S, Murthi M, et al. Effect of weight loss on recurrence of atrial fibrillation after ablative therapy: a systematic review and meta-analysis. J Interv Card Electrophysiol. 2022 Sep;64(3):763-71. Abstract
199. Brand-McCarthy SR, Delaney RK, Noseworthy PA. Can shared decision making improve stroke prevention in atrial fibrillation?: Implications of the updated guidelines. Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006080.Full text Abstract
200. Abed HS, Wittert GA, Leong DP, et al. Effect of weight reduction and cardiometabolic risk factor management on symptom burden and severity in patients with atrial fibrillation: a randomized clinical trial. JAMA. 2013 Nov 20;310(19):2050-60.Full text Abstract
201. Abdul-Aziz AA, Altawil M, Lyon A, et al. Lifestyle therapy for the management of atrial fibrillation. Am J Cardiol. 2018 May 1;121(9):1112-7. Abstract
202. Aldaas OM, Lupercio F, Han FT, et al. Meta-analysis of effect of modest (≥10%) weight loss in management of overweight and obese patients with atrial fibrillation. Am J Cardiol. 2019 Nov 15;124(10):1568-74. Abstract
203. Leggio M, Fusco A, Coraci D, et al. Exercise training and atrial fibrillation: a systematic review and literature analysis. Eur Rev Med Pharmacol Sci. 2021 Aug;25(16):5163-75.Full text Abstract
204. Oesterle A, Giancaterino S, Van Noord MG, et al. Effects of supervised exercise training on atrial fibrillation: a meta-analysis of randomized controlled trials. J Cardiopulm Rehabil Prev. 2022 Jul 1;42(4):258-65. Abstract
205. Ortega-Moral A, Valle-Sahagún B, Barón-Esquivias G. Efficacy of exercise in patients with atrial fibrillation: systematic review and meta-analysis. [in spa]. Med Clin (Barc). 2022 Oct 28;159(8):372-9. Abstract
206. Li X, Zhou X, Xu X, et al. Effects of continuous positive airway pressure treatment in obstructive sleep apnea patients with atrial fibrillation: a meta-analysis. Medicine (Baltimore). 2021 Apr 16;100(15):e25438.Full text Abstract
207. Choi S, Chang J, Kim K, et al. Association of smoking cessation after atrial fibrillation diagnosis on the risk of cardiovascular disease: a cohort study of South Korean men. BMC Public Health. 2020 Feb 3;20(1):168.Full text Abstract
208. Lee SR, Choi EK, Jung JH, et al. Smoking cessation after diagnosis of new-onset atrial fibrillation and the risk of stroke and death. J Clin Med. 2021 May 21;10(11):2238.Full text Abstract
209. Harskamp RE, Lucassen WAM, Lopes RD, et al. Risk of stroke and bleeding in relation to hypertension in anticoagulated patients with atrial fibrillation: a meta-analysis of randomised controlled trials. Acta Cardiol. 2022 May;77(3):191-5. Abstract
Use of this content is subject to our disclaimer